Blockchain Press Releases
Eleven Therapeutics Announces Research Collaboration with Novo Nordisk to Discover Cell-Specific Carriers of Nucleic Acid Therapeutics
CAMBRIDGE, Mass and CAMBRIDGE, England, July 17, 2023 /PRNewswire/ — Eleven Therapeutics, a biotechnology company developing next-generation RNA therapeutics through the mastery of combinatorial chemistry and artificial intelligence, today announced a research collaboration with the global healthcare company Novo Nordisk. Through this collaboration, the companies aim to identify novel molecules that promote precise delivery of nucleic acid by leveraging Eleven’s innovative DELiveri™ platform, ushering in a new era of precision in nucleic acid medicine for cardiometabolic diseases.
Nucleic acid therapeutics have immense potential for cardiometabolic diseases. However, the major challenge to their successful development as safe and effective agents is the paucity of organ-specific delivery agents. The DELiveri™ platform revolutionises the field of nucleic acid therapeutics by utilising DNA-encoded libraries (DELs) to discover conjugates that effectively deliver therapeutic molecules and present great promise for a multitude of potential therapeutic areas. This collaboration provides Novo Nordisk with exclusivity for specific cell types and applications associated with Eleven’s innovative DELiveri™ platform in a staged approach.
Uli Stilz, Head of Novo Nordisk’s Bio Innovation Hub in Boston, stated, “Our research collaboration with Eleven Therapeutics builds on Novo Nordisk’s commitment to advancing precision medicine and opens up the opportunity to learn from one another as we explore novel cell-specific targeting strategies. With the combination of our joint team’s expertise and using Eleven’s DELiveri™ platform, we can potentially unlock transformative treatments for people living with cardiometabolic diseases.”
Prof. Yaniv Erlich, CEO of Eleven Therapeutics, remarked, “We are delighted to collaborate with Novo Nordisk, a leader in global healthcare. Firstly, this collaboration has the potential for immense positive impact on patients’ lives through the multitude of therapeutic cargos each of the discovered carriers could afford. Furthermore, it is a testament to the promise of our DELiveri™ platform, which is uniquely tailored to discover cell-selective delivery moieties — small molecules and other types — at an efficiency level yet to be observed in this field, thanks to the throughput capabilities of DELs.”
Eleven Therapeutics is committed to maximising the impact of the DELiveri™ platform for the benefit of patients through expanding collaboration with innovative partners working in specific cell-type and disease area applications. Novo Nordisk’s Bio Innovation Hub is an R&D unit designed to bring cutting-edge life science innovation from bench to bedside through co-creation partnerships, with a strategic focus within cardiometabolic, rare endocrine, and blood disorders.
About the DELiveriTM Platform
Eleven Therapeutics’ DELiveri™ platform presents a game-changing approach to the delivery of nucleic acid therapeutics, overcoming the many complex challenges that plague the field. DELiveri™ uses DNA-encoded libraries (DELs) to discover conjugates that effectively deliver therapeutic molecules into target cell types of interest. This innovation obviates a key obstacle: the requirement for multiple conditions to co-occur simultaneously. Instead, DELiveri™ harnesses DEL to identify novel cell-specific internalising molecules via hypothesis-free, high-throughput screening of a vast number of small molecules. Traditional direct DEL screens struggle to differentiate between molecules that successfully internalise cargo into the cytoplasm and those that remain on the cell’s outer membrane or become trapped in inaccessible organelles. To overcome this limitation, Eleven’s DELiveri™ platform was engineered as a synthetic biology solution, transforming screened cells into molecular radars. The resulting signals are transformed into quantitative scores that describe the delivery potential of each molecule in the library. Utilizing ML/AI tools, Eleven is able to pinpoint molecules that promote cell specific delivery of nucleic acid therapeutics.
About Eleven Therapeutics
Eleven Therapeutics ushers in the next generation of RNA therapeutics by mastering combinatorial chemistry, synthetic biology and AI. Our pipeline is comprised of extended-release mRNA therapeutics — dubbed xRNA — addressing unmet medical needs in the metabolic, hematologic and infectious disease areas, as well as prophylactic siRNAs for pandemic-poised viral infections. The pipeline is enabled by our proprietary high throughput screening platforms, TERA™ and DELiveri™, which, respectively, generate chemically modified xRNAs and cell-penetrating delivery carriers. The company was founded in 2020 by world-leading, interdisciplinary scientists in Cambridge (UK), Boston (US), and Tel Aviv (Israel), capitalising on the world’s top talent pools. Eleven Tx was seeded by top VCs and the Bill & Melinda Gates Foundation.
Contacts
Era Duek
VP Research Operations
Email: [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/eleven-therapeutics-announces-research-collaboration-with-novo-nordisk-to-discover-cell-specific-carriers-of-nucleic-acid-therapeutics-301878266.html
Blockchain
Crypto Case Tests SEC’s Ability to Police Blockchain Technology
A New York judge will soon address complex regulatory issues in the case involving Richard Heart, founder of the crypto token Hex. The SEC has accused Heart of selling unregistered securities and misusing investor funds to purchase luxury items, such as a $1.38 million Rolex and a 555-carat black diamond called “The Enigma.” Heart, based in Finland, is seeking dismissal of the SEC’s case, arguing that the SEC has overreached in its attempt to regulate global blockchain technology.
The case highlights the challenges of enforcing US securities laws on decentralized finance (DeFi) platforms and borderless crypto transactions. Heart and his supporters argue that technological innovations like Hex and the PulseChain blockchain cannot be defendants in such cases. This dispute underscores the evolving nature of blockchain technology and the difficulty regulators face in applying traditional legal concepts to these new digital assets.
The SEC has broadened its scrutiny of DeFi, with investigations and enforcement actions against various firms. However, the SEC’s approach of naming software and blockchain protocols as defendants raises concerns about developer liability and potential overreach. The outcome of this case could set significant precedents for how the US regulates the crypto industry.
Legal experts note that the SEC’s strategy might lead to developers being held accountable for the software they create, which could discourage innovation in the blockchain space. The case also raises jurisdictional questions, as Heart argues that US courts should not have authority over his actions, given his lack of direct ties to the US.
The resolution of this case could have broad implications for the regulation of decentralized and international crypto projects, as it tests the SEC’s ability to police a rapidly evolving and inherently global technology.
Source: news.bloomberglaw.com
The post Crypto Case Tests SEC’s Ability to Police Blockchain Technology appeared first on HIPTHER Alerts.
Blockchain
Binance Announces Adjustment of Tick Size for Spot Trading Pairs
Binance, a leading cryptocurrency exchange, has announced adjustments to the tick size (the minimum change in the unit price) of specific spot trading pairs. These adjustments are aimed at enhancing market liquidity and improving the overall trading experience for users. The changes are scheduled to be completed by 05:00 (UTC) and 07:00 (UTC) on May 23, 2024.
Traders can find details about the tick sizes of all spot trading pairs on Binance in the platform’s Trading Rules. Importantly, the adjustment will not impact spot trading and related functionalities. API users will also observe changes in the tick size, and they can stay updated with the latest tick size using the GET /api/v3/exchangeInfo endpoint. Additional details and updates can be found in the API Changelog.
Existing spot orders will not be affected by the tick size update. Orders placed before the update will continue to be matched with the original tick size. However, traders are advised to adjust their trading strategies accordingly to avoid any unnecessary impact on their trading activities.
Binance emphasizes the importance of referencing the English version of the announcement for the most accurate and up-to-date information, as there may be discrepancies in translated versions. The exchange remains committed to providing a seamless trading experience and appreciates the support of its users. Users are reminded to exercise caution and make informed decisions when trading on the platform.
Source: blockchain.news
The post Binance Announces Adjustment of Tick Size for Spot Trading Pairs appeared first on HIPTHER Alerts.
Blockchain
OKX Announces Support for New USDC Spot Trading Pairs
According to an official announcement released on May 16, 2024, OKX will introduce new USDC trading pairs in the spot trading section between 7:00 am and 8:00 am UTC on May 20, 2024. This addition aims to broaden trading options for OKX users and contribute to the expanding USDC ecosystem.
In light of the risks associated with digital asset trading, OKX has issued a cautionary note to all users. They emphasize that information provided by OKX and third parties is for informational and educational purposes only. OKX does not guarantee the accuracy or completeness of any information and does not provide financial, investment, or other forms of advice.
OKX highlights the speculative nature and high volatility of digital assets, cautioning that they may become illiquid at any time, potentially resulting in the loss of the entire investment. Therefore, OKX advises users to conduct thorough research and assess their risk tolerance before engaging in digital asset trading.
For inquiries regarding the new USDC spot trading pairs or any other concerns, users can contact OKX through their support center or engage with the OKX team on various platforms. OKX’s proactive approach in addressing user inquiries and fostering community interaction underscores its commitment to user satisfaction and the overall growth of the crypto ecosystem.
Source: blockchain.news
The post OKX Announces Support for New USDC Spot Trading Pairs appeared first on HIPTHER Alerts.
-
Blockchain Press Releases2 days ago
Swaps Launches Innovative Payment Links for Crypto and Fiat Transactions
-
Blockchain7 days ago
BHE Exchange: Redefining the Future of Digital Asset Trading
-
Blockchain Press Releases7 days ago
Venom and KuCoin Ventures forge strategic partnership
-
Blockchain4 days ago
RevoluGROUP Canada Inc. Announces Leave of Absence for Chairman Bernard Lonis
-
Blockchain Press Releases3 days ago
KuCoin Research Report Reveals: $1 Billion in Financing and Rising Stablecoin Issuance Amid Market Fluctuations
-
Blockchain3 days ago
Tornado Cash dev Alexey Pertsev gets 64-month prison term after Dutch court finds him guilty of money laundering
-
Blockchain Press Releases2 days ago
OKX, Circle, and Bitrue Among Sponsors of Consensus 2024
-
Blockchain3 days ago
OrdinalsBot Behind 80% of the Largest Files Inscribed on Bitcoin Blockchain; Announces Revenue, Growth and Partnerships